ArticleAnnals of nuclear medicine2026
Dual-time-point 68Ga-FAPI PET/CT in gastrointestinal malignancies: head-to-head comparison with 18 F-FDG for lesion detection and patient-level assessment.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the diagnostic performance of 18 F-Fluorodeoxyglucose (FDG) and 68Ga-fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) in gastrointestinal malignancies, with particular emphasis on lesion detection, peritoneal disease assessment, and the potential added value of dual-time-point FAPI imaging.
methodsThirty-eight patients with histologically confirmed gastrointestinal cancers who underwent both FDG and FAPI PET/CT within a 4-week interval were retrospectively analyzed. FAPI PET/CT images were acquired at 10 and 60 min after tracer injection. Patient-level analyses (staging/restaging accuracy, impact on management) and lesion-based analyses (detection rate, characterization, maximum standardized uptake value [SUVmax] dynamics, lesion size) were evaluated against follow-up data as the reference standard.
resultsFAPI PET/CT demonstrated superior agreement with the reference standard compared with FDG PET/CT for staging and restaging (κ = 0.91 vs. 0.32). On lesion-based analysis, FAPI showed markedly higher detection rate for malignant lesions (86% vs. 34%) and fewer indeterminate findings. Median peritoneal carcinomatosis index score and the number of detected malignant lesions per patient were significantly higher with FAPI PET/CT (p < 0.001). Dual-time-point FAPI imaging revealed a significant increase in SUVmax from early to later time points in malignant lesions, whereas benign lesions showed no significant change. Larger lesions (> 10 mm) demonstrated more pronounced delayed uptake, and greater early-to-delayed SUVmax increases were independently associated with malignancy, suggesting a potential role for dynamic uptake patterns in lesion characterization.
conclusionsDual-time-point 68Ga-FAPI PET/CT demonstrated superior lesion detectability compared with FDG PET/CT in gastrointestinal malignancies and may help reduce diagnostic uncertainty. These findings suggest that dual-time-point FAPI imaging may provide incremental value for lesion characterization and support its complementary role in oncologic imaging.
Indexed as
Identifiers
42348133What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.